cysteamine hydrochloride
PreclinicalSmall molecule
cysteamine hydrochloride is one of 9 small molecule programs targeting Cystinosis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Cystinosis
#DrugCompanyPhaseTrials
1Acetadote
AArbor Pharmaceuticals, Inc.
Approved
N-Acetyl Cyteien
SStanford University
Approved
RP103
AmgenPhase 3
Cystagon
AmgenPhase 2
ELX-02
EEloxx Pharmaceuticals, Inc.
Phase 2
Cystadrops
LLeadiant Biosciences, Inc.
Preclinical
Procysbi
HHorizon Therapeutics Ireland DAC
Preclinical
N-Acetylcysteine Amide
NNacuity Pharmaceuticals, Inc.
Preclinical
cysteamine hydrochloride
FFDA Office of Orphan Products Development
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cystinosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for cysteamine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details